Previous close | 52.20 |
Open | 53.79 |
Bid | 54.06 x 200 |
Ask | 54.24 x 100 |
Day's range | 52.26 - 54.77 |
52-week range | 14.19 - 72.29 |
Volume | |
Avg. volume | 697,546 |
Market cap | 3.167B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 85.80 |
Key Insights Institutions' substantial holdings in Apogee Therapeutics implies that they have significant influence...
Apogee (APGE) surges 95.6% in a month after reporting positive interim results from its phase I study for APG777 to treat AD. The company plans to initiate a phase II study for the same indication.
Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing every two weeks for other biologics in development Second product candidate to enter the clinic following positive interim results from Phase 1 Healthy Volunteer Trial for APG777, which exceeded all of its trial objectives Interim subcutaneous safety and pharmacokinetic data from healthy volunteers